콘텐츠로 건너뛰기
주식/증권 📉 부정적

Sarepta Stock Slumps. Why an Earnings Beat Wasn’t Enough for the S&P 500 Loser.

요약

Sarepta Therapeutics is seeing lower demand for its flagship gene therapy, Elevidys, following a regulatory crackdown.